RxDoctor Payments Data

Jeffrey Snyder, MD

Cardiovascular Disease · Allentown, PANPI 1851384234

Payments from drug & device makers

$1,257in general payments, 2019–2025

Across 40 payments — averaging $31.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$391
  • Boston Scientific$389
  • Edwards Lifesciences$194
  • Abiomed$101
  • Pfizer$40
  • E.r. Squibb & Sons, L.L.C.$37
  • plus $106 from 7 others

What the payments were for

  • Food & beverage$1,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,257 in reported general payments places this provider in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,854
Medicare patients
755
Services billed
1,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$357,686
XareltoRivaroxaban74$89,482
EntrestoSacubitril/Valsartan31$28,324
Repatha SureclickEvolocumab37$23,042
Dofetilide33$12,287
Metoprolol Succinate434$8,834
ClopidogrelClopidogrel Bisulfate205$3,766
Atorvastatin Calcium246$3,624
NorvascAmlodipine Besylate11$2,712
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,648
Ranolazine ErRanolazine16$2,573
Valsartan39$2,407
Rosuvastatin Calcium164$2,197
Toprol XlMetoprolol Succinate26$2,121
Losartan Potassium181$2,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$357,686318 claims
NovartisEntresto$14$28,32431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →